Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
VERTICAL TRANSMISSION PREVENTION Best Practices www.hivnet.ubc.ca Amy Slogrove 19 July 2016 CTN PMTCT Symposium AIDS 2016, Durban, South Africa www.hivnet.ubc.ca New HIV Infections in Children: 2001-2015 150 000 But: 1.5 million women living with HIV give birth each year – unchanged >50% of pregnant women in LMICs do not receive an HIV-test www.hivnet.ubc.ca Hot off the press... Key updates related to PMTCT Best practices for a public health approach in high prevalence settings www.hivnet.ubc.ca Overview 1. Timing of HIV Testing • Pregnant women & infants 2. Maternal Antiretroviral Therapy (ART) • Maternal Health & PMTCT 3. Infant Prophylaxis 4. Research Gaps / Responsibilities 5. Take Home Messages www.hivnet.ubc.ca Timing of HIV Testing: pregnant women HIV Viral Load Highest Risk Time Summary • Routine component of care • All HIV-negative pregnant women retested third trimester, labour, postpartum • Lactating mothers retested periodically Evidence • 4% of breastfeeding women acquired HIV-infection during pregnancy or while breastfeeding (Kenya, Malawi, SA) • 20% of postpartum transmission due to new HIV-infection in women while pregnant/breastfeeding (Zimbabwe) www.hivnet.ubc.ca Timing of HIV Testing: pregnant women HIV Viral Load Highest Risk Time www.hivnet.ubc.ca Timing of HIV Testing: HIV-exposed infants Waning of infant maternally-derived antibody levels Birth Summary • 4-6 weeks all HEI: virologic testing (DNA-PCR) • 9 months all HEI: screen with serologic test, if reactive confirm with virologic test • Breastfeeding HEI: serologic test @ 18 months or 3 months after breastfeeding cessation 9 months 18 months Evidence • CHER trial – rapid HIV progression < 12 weeks of age • Rapid serologic tests @ 9 months – sensitivity 99.8% (95%CI 99.5-100%) • Discussion around value of PCR @ birth www.hivnet.ubc.ca Timing of HIV Testing: Outside of PMTCT Programs Inpatient Outpatient Developmental Delay PMTCT programs Summary: More testing • Inpatient care (diarrhoea, pneumonia, sepsis) • Outpatient care (malnutrition, IMCI & TB clinics) • (Developmental delay) • Parents, siblings diagnosed with HIV Parent/Sibling Evidence • 22% of paediatric inpatients – undiagnosed HIV infection (Systematic review) • 25% of malnutrition clinic attendants (Eastern & Southern Africa) • Highly acceptable to parents & caregivers www.hivnet.ubc.ca Maternal ART Summary • Simple! • Better for maternal health • Better for PMTCT • Better for programs Evidence • RCTs: TEMPRANO & START - adults • PROMISE: HIV transmission with triple ART (0.6%) vs. AZT+sdNVP (1.8%) • Malawi, South Africa – program feasibility www.hivnet.ubc.ca Maternal ART www.hivnet.ubc.ca Infant Prophylaxis Summary High risk infants – born to women with: • • • • < 4 weeks ART prior to delivery Viral load > 1000 copies/ml within 4 weeks prior to delivery Incident HIV infection during pregnancy or while breastfeeding HIV only identified postpartum Infant dual prophylaxis (AZT+NVP) • • Breastfed – 12 weeks Formula – 6 weeks Not high risk • • Mothers on ART > 4 weeks VL < 1000 during last 4 weeks of pregnancy Infant NVP prophylaxis • • Breastfed – 6 weeks Formula – 4 to 6 weeks Evidence • • HPTN040 – no ARVs during pregnancy; 2/3 drug infant prophylaxis better than 1 HPTN046 – breastfed infants, mothers on ART; no difference in PN transmission with 6 weeks vs. 6 months of infant NVP www.hivnet.ubc.ca Infant Prophylaxis – just a bridge Maternal viral load & duration of maternal ART are key determinants of transmission risk www.hivnet.ubc.ca Research Gaps / Responsibilities • Maternal & Infant HIV Testing • Better understanding of mothers responses to negative HIV results – testing fatigue? • Does birth testing add value for PMTCT programs, infants & families? • Universal maternal ART • TDF/3TC/EFV as effective for PMTCT as the LPV/r based PROMISE regimens? • Effect of ART on pregnancy outcomes & short/ long-term HIV-exposed infant outcomes? • Infant prophylaxis • Is NVP+AZT the right dual therapy combination for high risk infants? • What is appropriate prophylaxis for infants of mothers on failing regimens / with drug resistance ? • Breastfeeding • Family & community acceptability of interventions, services, delivery strategies www.hivnet.ubc.ca Take Home Messages 1. Test, test & test again • Pregnant women, HIV-exposed infants & outside of PMTCT programs 2. Universal maternal ART • Best for maternal health & also most effective for PMTCT 3. Infant prophylaxis • Only a bridge & high risk infants need a stronger bridge 4. Research responsibilities • Many 5. Invest in research competencies www.hivnet.ubc.ca Acknowledgments CTN International Postdoctoral Fellowship Award 2013-2014 Joel Singer & Jacquie Sas Stellenbosch University University of British Columbia University of Cape Town